MiNK Therapeutics Net Cash Flow 2020-2025 | INKT

MiNK Therapeutics net cash flow from 2020 to 2025. Net cash flow can be defined as the total change in cash for the company over the given period.

MiNK Therapeutics Net Cash Flow 2020-2025 | INKT

MiNK Therapeutics net cash flow from 2020 to 2025. Net cash flow can be defined as the total change in cash for the company over the given period.
Related Stocks
Company NameMarket
Cap
AstraZeneca (AZN)$220.6B
Amgen (AMGN)$158.8B
Gilead Sciences (GILD)$136.4B
Vertex Pharmaceuticals (VRTX)$120.4B
Bristol Myers Squibb (BMY)$95.4B
GSK (GSK)$78.4B
CSL (CSLLY)$76.6B
Regeneron Pharmaceuticals (REGN)$61.3B
Alnylam Pharmaceuticals (ALNY)$41.1B
Argenex SE (ARGX)$34.3B
BioNTech SE (BNTX)$27.1B
Royalty Pharma (RPRX)$20.2B
Biogen (BIIB)$19.7B
Insmed (INSM)$18.6B
Illumina (ILMN)$15.7B
Genmab (GNMSF)$14.2B
Genmab (GMAB)$13.7B
Incyte (INCY)$13.3B
Moderna (MRNA)$13B
Exelixis (EXEL)$12.2B
BioMarin Pharmaceutical (BMRN)$11.1B
QIAGEN (QGEN)$10.7B
Ascendis Pharma (ASND)$10.7B
Swedish Orphan Biovitrum (BIOVF)$10.4B
Exact Sciences (EXAS)$9.8B
Verona Pharma American Depositary Share (VRNA)$8.9B
Bio-Techne Corp (TECH)$8.5B
Blueprint Medicines (BPMC)$8.4B
Roivant Sciences (ROIV)$7.7B
Repligen (RGEN)$7.3B